This site is intended for healthcare professionals

Diagnóza, interval podávania a protilátky proti liečivu predikujú hladinu infliximabu u IBD pacientov na udržiavacej liečbe

Krajcovicova Anna1, Batovsky Marian2, Gregus Milos1, 3, Hlista Milan4, Durina Juraj5, Leskova Zuzana1, Sturdik Igor1, Koller Tomas1, Toth Jozef1, Huorka Martin1, Hlavaty Tibor1

1 Comenius University, Faculty of Medicine, 5th department of Internal Medicine, University Hospital, Bratislava, Slovak Republic
2 Clinic of Gastroenterology, University Hospital Bratislava, Slovak Republic
3 Gastroenterology and Hepatology Centre, Nitra, Slovak Republic
4 Centre of Gastroenterology, Department of Internal Medicine, Teaching Hospital, Trenčín, Slovak Republic
5 Gastroenterology Centre, Department of Internal Medicine, Faculty Hospital Nové Zámky, Slovak Republic

Abstract Objective The aims of the study were to identify clinical factors influencing trough levels (TL) of infliximab (IFX) in patients with inflammatory bowel disease (IBD) and to determine the impact of the presence of antidrug antibodies (ADA) on IFX TL.   Methods This was a multicentre retrospective cross-sectional study performed at 5 large IBD centres...

Zpět

Paediatric News 1/2025

03 | 04 | 2025

Již brzy vyjde nové číslo časopisu Paediatric News.

Česká diabetologie 1/2025

31 | 03 | 2025

Připravujeme první letošní číslo časopisu Česká diabetologie.

Onemocnění hltanu a jícnu

27 | 03 | 2025

Právě vyšel pátý svazek reedice Albertovy sbírky.




Partneři projektu